The Emergence of Direct-to-Employer Pharmacy Programs
The pharmacy benefit supply chain is under more scrutiny than at any point in its history. The Consolidated Appropriations Act now classifies PBMs as covered service providers under ERISA, requiring full compensation disclosure and rebate pass-through. Congressional hearings have put intermediary economics on the public record. And the rise of GLP-1 medications, with annual list prices exceeding $15,000 per patient, has made high-cost drug spend a board-level concern for every self-funded employer in the country.
Against this backdrop, a structural alternative is gaining traction: the direct-to-employer pharmacy benefit program. In a DTE model, manufacturers make their pricing available to employer-sponsored health plans through dedicated pharmacy benefit infrastructure, rather than routing it through the traditional PBM adjudication and distribution chain. The employer accesses manufacturer-direct drug pricing inside the benefit. Members receive their medications through licensed pharmacies. And the transaction is documented at the decision level, not summarized in a quarterly rebate report months after the fact.
This is not a theoretical concept. The infrastructure exists today, and the legislative environment is accelerating adoption.
How Traditional Pharmacy Benefit Distribution Works
To understand why DTE programs are emerging, it helps to understand where costs accumulate in the traditional model.
When a physician writes a prescription for a high-cost specialty drug, the medication typically moves through a chain that includes a wholesale distributor, a specialty pharmacy (often owned by or affiliated with the PBM), and eventually the patient. At each stage, margin is extracted. The wholesaler takes a distribution fee. The PBM may capture spread between what it charges the plan and what it pays the pharmacy. Rebates negotiated with the manufacturer are held for 90 to 180 days before any portion reaches the employer, and the percentage that actually passes through varies widely depending on contract terms.
The plan sponsor, who bears the actual cost of the drug, has limited visibility into these layers. Reporting is typically aggregated. Rebate reconciliation happens quarterly at best. And the entity making the routing decision often has financial relationships with the dispensing channels being evaluated, creating an inherent structural conflict.
For generic and low-cost brand drugs, the economics of this system are manageable. But for high-cost specialty medications and GLP-1 therapies, where a single drug can represent hundreds of thousands of dollars in annual plan spend, these accumulated intermediary costs become material. Self-funded employers are increasingly asking whether a more direct path exists.
What "Direct-to-Employer" Actually Means
The term "direct-to-employer" describes a model in which manufacturer pricing reaches the employer-sponsored health plan without passing through the traditional PBM adjudication and distribution chain. This does not mean the manufacturer contracts directly with individual employers. In practice, the manufacturer works through a pharmacy benefit infrastructure platform that facilitates the compliant connection between manufacturer pricing and the employer's plan.
In a DTE arrangement, the manufacturer sets a price for the drug, typically WAC minus a program rebate defined in a supply agreement. The infrastructure platform receives electronic prescriptions, verifies member eligibility against the employer's plan, routes the prescription to a licensed pharmacy for fulfillment, collects member cost-share, and settles with the manufacturer. The employer gets manufacturer-direct drug pricing applied inside the benefit, meaning the transaction counts toward deductibles and accumulators just like any other covered prescription.
This is a meaningful distinction from direct-to-consumer (DTC) programs, where the patient pays out of pocket, or direct-to-patient (DTP) models that often sit outside the benefit entirely. In a DTE program, the prescription is a covered benefit. The employer sees it in their claims data. The member's cost-share applies normally. The only difference is that the drug was sourced through a channel with fewer intermediaries and lower total cost.
The Operational Infrastructure Required
A DTE program cannot function on a pricing agreement alone. The reason this model has been slow to develop is not a lack of manufacturer interest. It is the complexity of the operational infrastructure required to make the model compliant, scalable, and integrated with the existing benefit.
At minimum, a functioning DTE program requires electronic prescription intake through standard NCPDP SCRIPT workflows, so prescribers do not need to change their behavior. It requires real-time eligibility verification against the employer's plan, so only enrolled members with qualifying prescriptions enter the program. It requires DSCSA compliance, specifically per-prescription T3 documentation for serialized products, which is a significant technical challenge when the distribution model does not follow a traditional wholesale chain of custody.
Beyond intake and compliance, the infrastructure must handle fulfillment routing to licensed pharmacies, member engagement for pharmacy selection and cost-share collection, medical claim billing to the employer's TPA for data continuity, accumulator reporting so the member's spend counts toward their deductible and out-of-pocket maximum, and financial settlement with the manufacturer, pharmacy, and plan.
Each of these functions must work together in a single integrated system. A gap in any one area creates compliance risk, member confusion, or financial reconciliation problems. This is why pharmacy benefit infrastructure is the core enabler of the DTE model, not the pricing agreement itself.
Who DTE Programs Are Right For
Not every employer is a candidate for a DTE program. The model is most relevant for self-funded employers, because they bear the direct cost of their members' drug spend and have the fiduciary obligation and financial incentive to seek the lowest net cost for each prescription.
In practice, the strongest fit is a self-funded employer with 500 or more covered employees, meaningful specialty drug or GLP-1 utilization, and a willingness to carve out targeted high-cost drugs from their PBM's standard adjudication. The employer does not need to replace their PBM or their TPA. They need to add a parallel channel for the specific drugs where manufacturer-direct pricing produces a materially lower net cost.
Employers with concentrated spend in a small number of high-cost categories see the most immediate impact. A plan with 20 members on GLP-1 medications at $15,000 per year each is spending $300,000 annually on those drugs alone. If manufacturer-direct drug pricing reduces the net cost by 25 to 40 percent on those specific prescriptions, the savings are significant and measurable, without touching the rest of the formulary.
The model also appeals to employers who face fiduciary scrutiny under ERISA and the Consolidated Appropriations Act. A DTE program that produces decision-level documentation for every routing choice gives the plan sponsor a concrete record of prudent oversight, something that aggregated PBM reporting cannot provide.
How DTE Works Alongside a PBM
A common misconception is that a direct-to-employer pharmacy program requires replacing the PBM. It does not. The PBM continues to administer the broad formulary, process standard claims, and manage the pharmacy network for the majority of prescriptions. The DTE program operates alongside it, handling only the targeted high-cost drugs that the employer has configured for the program.
When a prescription comes in for a drug that is in scope, the DTE infrastructure evaluates it against all available channels in real time, including the PBM's standard pricing, manufacturer-direct pricing, and any other activated supply paths. If the manufacturer-direct channel produces the lowest net cost, the prescription is routed through that channel. If the PBM channel is lower, the prescription stays with the PBM. Every decision is documented with the channels compared, the rules applied, and the rationale for the routing choice.
This is not a replacement strategy. It is an optimization layer for the drugs where intermediary costs are highest and where manufacturer-direct access produces the greatest savings. The employer's existing benefit administration, TPA, and PBM relationships remain intact.
Building Toward a More Accountable Benefit
The direct-to-employer pharmacy model is not a workaround or a temporary cost play. It is a structural shift in how high-cost drugs reach the people who need them, with fewer intermediaries, lower total cost, and verifiable documentation at every step.
For employers exploring this model, the critical question is not whether DTE makes economic sense. The math is straightforward. The question is whether the pharmacy benefit infrastructure exists to make it operational, compliant, and integrated with the existing benefit.
ApalyRx provides that infrastructure. As a licensed centralized prescription processing pharmacy, ApalyRx handles eRx intake, eligibility, DSCSA compliance, fulfillment routing, settlement, and decision-level documentation for every prescription. For self-funded employers ready to access manufacturer-direct drug pricing inside their benefit, start here. For manufacturers building a direct-to-employer channel, learn how the infrastructure works.